Carv­ing a pipeline out of trou­bled Te­va, Or­biMed leads $60M launch of new NASH play­er

Te­va $TE­VA has had a rough year. Plagued by crip­pling debt, the Is­raeli gener­ics gi­ant has un­der­gone a mas­sive reck­on­ing that cul­mi­nat­ed in an ex­ec­u­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.